M
Michael Brada
Researcher at Clatterbridge Cancer Centre NHS Foundation Trust
Publications - 223
Citations - 14927
Michael Brada is an academic researcher from Clatterbridge Cancer Centre NHS Foundation Trust. The author has contributed to research in topics: Radiation therapy & Radiosurgery. The author has an hindex of 66, co-authored 221 publications receiving 13955 citations. Previous affiliations of Michael Brada include University of Liverpool & Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
W. K. A. Yung,Robert E. Albright,Jeffrey J. Olson,R Fredericks,Karen Fink,Michael D. Prados,Michael Brada,Alexander M. Spence,Raymond J. Hohl,William R. Shapiro,Michael Glantz,Harry S. Greenberg,Robert G. Selker,Nicholas A. Vick,R. Rampling,Henry S. Friedman,Peter C. Phillips,Janet M. Bruner,N. Yue,David Osoba,S Zaknoen,Victor A. Levin +21 more
TL;DR: Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 months in the PCB group, and freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received.
Journal ArticleDOI
Pathology and Genetics of Tumours of the Nervous System
TL;DR: Paul Kleihues and Webster Cavenee, eds, pp 314, IARC Press, Lyon 2000.
Journal ArticleDOI
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
TL;DR: This work presents a meta-analyses of the prophylactic and descriptive literature reviews that show clear trends in prognosis and pre-operatively diagnosed patients with atypical central giant cell granuloma have poorer prognosis after surgery than other models.
Journal ArticleDOI
Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma.
Michael Brada,D. Ford,Stanley W. Ashley,Judith M Bliss,S. Crowley,Mark Mason,B. Rajan,D. Traish +7 more
TL;DR: There is an increased risk of second intracranial tumour in patients with pituitary adenoma treated with surgery and radiotherapy, and radiation is likely to be the most important factor contributing to the excess risk.
Journal ArticleDOI
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Michael Brada,Khê Hoang-Xuan,R. Rampling,Pierre Yves Dietrich,Luc Dirix,David R. Macdonald,J. J. Heimans,B. A. Zonnenberg,Jose Bravo-Marques,Roger Henriksson,Roger Stupp,N. Yue,Janet M. Bruner,M. Dugan,S. Rao,Sara L. Zaknoen +15 more
TL;DR: Temozolomide demonstrated modest clinical efficacy, with an acceptable safety profile and measurable improvement in quality of life in patients with recurrent GBM, and should be explored further in an adjuvant setting and in combination with other agents.